AngioDynamics Inc.
ANGO | NASDAQ
$15.42
-$0.02 (-0.13%)
At close: Sep 21, 2026, 4:00 PM ET
$15.42
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Key Executives
| Name | Position |
|---|---|
| James C. Clemmer | Chief Executive Officer, President & Director |
| Lawrence T. Weiss | Senior Vice President, Chief Legal Officer & Corporate Secretary |
| Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer |
| Benjamin H. Davis | Senior Vice President of Business Development & Strategy |
| Chad T. Campbell | Senior Vice President and GM of Oncology & Interventional Devices |
| Jake Brumbaugh | Global Vice President for Marketing-Oncology |
| Juan Carlos Serna | Senior Vice President of Scientific & Clinical Affairs |
| Kim L. Seabury | Senior Vice President of Information Technology |
| Laura Piccinini | Senior Vice President & GM of Cardiovascular and International |
| Marna I. Bronfen-Moore | Senior Vice President of Human Resources |
| Saleem Cheeks | Vice President of Communications |
| Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain |
AngioDynamics Inc.
| Country | United States |
| IPO Date | May 31, 2004 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 632 |
| CEO | James C. Clemmer |
Contact Details
14 Plaza Drive Latham,
New York 12110 United States
Stock Details
| Ticker Symbol | ANGO |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001275187 |
| CUSIP Number | 03475V101 |
| ISIN Number | US03475V1017 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove ANGO